People · Operator
Named in public records as an officer, director or promoter · active 2013–2025 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sparrow Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $73.3M | $386.2M | 2020 |
| Symbiomix Therapeutics, LLC | — | Pharmaceuticals | Series B | $25.5M | $204.0M | 2013 |
Robert Jacks at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Jacks on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Klaus Veitinger | 2 | 6 |
| Peter Thompson | 1 | 16 |
| Jonathan Root | 1 | 16 |
| Rishi Gupta | 1 | 12 |
| Ben Auspitz | 1 | 9 |
| Thomas Beck | 1 | 7 |
| Niall O'Donnell | 1 | 7 |
| David Katz | 1 | 6 |
| Zach Scheiner | 1 | 6 |
| Karen Dawes | 1 | 2 |
| Joseph Amprey | 1 | 2 |
| Nanna L?neborg | 1 | 1 |
| David Aaron Katz | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.